Brinretigene Vesgedparvovec for leber congenital amaurosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Mar 2019: Trial registered, NCT03872479
  2. 26 Sep 2019: Trial started, NCT03872479

The trials

NCT03872479: Single Ascending Dose Study in Participants With LCA10

State
State not given
Phase
Phase 1 and Phase 2
People
34 planned
Started
26 Sep 2019
Primary completion
23 May 2025
Arms
Adults Low Dose, Adults Middle Dose, Adults High Dose, Pediatric Middle Dose, Pediatric High Dose
Results
None posted
  1. 13 Mar 2019: Trial registered
  2. 26 Sep 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.